FDA’s Priority Review of AXS-05 for Alzheimer’s Agitation Sets April 2026 Decision—What Could This Mean for Axsome Therapeutics?
Market Chameleon (Wed, 31-Dec 10:28 AM)
FDA Grants Priority Review to Axsome’s AXS-05 for Alzheimer's Agitation—Decision Expected by April 2026
Market Chameleon (Wed, 31-Dec 7:59 AM)
Axsome's Prescription Growth, Expanding Coverage, and Advancing Pipeline Signal Confidence Despite Ongoing Losses
Market Chameleon (Mon, 3-Nov 9:41 AM)
